• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Peritoneal Tumor - Pipeline Review, H2 2012 Product Image

Peritoneal Tumor - Pipeline Review, H2 2012

  • ID: 2245221
  • September 2012
  • 298 pages
  • Global Markets Direct

Peritoneal Tumor – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Peritoneal Tumor - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Tumor. Peritoneal Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Peritoneal Tumor.
- A review of the Peritoneal Tumor products under development by companies and universities/research institutes READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Peritoneal Tumor Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Peritoneal Tumor 11
Peritoneal Tumor Therapeutics under Development by Companies 13
Peritoneal Tumor Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Peritoneal Tumor Therapeutics – Products under Development by Companies 24
Peritoneal Tumor Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Peritoneal Tumor Therapeutics Development 33
Boehringer Ingelheim GmbH 33
F. Hoffmann-La Roche Ltd. 34
Abbott Laboratories 35
Amgen Inc. 36
Sanofi-Aventis 37
Eli Lilly and Company 38
Millennium Pharmaceuticals, Inc. 39
Cell Therapeutics, Inc. 40
Bayer AG 41
Marshall Edwards, Inc. 42
MabVax Therapeutics, Inc. 43
CritiTech, Inc. 44
TRACON Pharmaceuticals, Inc. 45
RECEPTA Biopharma S.A. 46
Theradex Systems, Inc. 47
Peritoneal Tumor – Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 55
trebananib - Drug Profile 55
enzastaurin hydrochloride - Drug Profile 57
sorafenib tosylate - Drug Profile 59
paclitaxel poliglumex - Drug Profile 61
ramucirumab - Drug Profile 63
taurolidine - Drug Profile 65
Vorinostat + Carboplatin + Gemcitabine - Drug Profile 66
imatinib mesylate - Drug Profile 67
Flavopiridol + Cisplatin - Drug Profile 68
cisplatin - Drug Profile 70
NSC-603071 - Drug Profile 71
BMS-247550 + Doxil - Drug Profile 72
Pazopanib + Doxil - Drug Profile 74
Topotecan + Iressa - Drug Profile 76
Avastin + Oxaliplatin + Paclitaxel - Drug Profile 77
Oxaliplatin + Floxuridine + Leucovorin - Drug Profile 78
Cytoxan + Celebrex - Drug Profile 79
Oxaliplatin + Topotecan - Drug Profile 80
Bryostatin 1 + Cisplatin - Drug Profile 81
Avastin + Erlotinib + Paclitaxel + Carboplatin - Drug Profile 82
Everolimus + Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 84
sargramostim - Drug Profile 86
BAY 43-9006 + Paclitaxel + Carboplatin - Drug Profile 87
bendamustine hydrochloride - Drug Profile 89
Paclitaxel + Cisplatin - Drug Profile 90
Phenoxodiol + Carboplatin - Drug Profile 91
Bevacizumab + Carboplatin + Gemcitabine - Drug Profile 93
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 95
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 97
sunitinib malate - Drug Profile 99
veliparib - Drug Profile 100
motesanib diphosphate - Drug Profile 101
fenretinide - Drug Profile 102
Carboplatin + Ifosfamide - Drug Profile 104
Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile 106
Carboplatin + Paclitaxel + Cediranib - Drug Profile 108
pemetrexed disodium - Drug Profile 110
Carboplatin + Topotecan - Drug Profile 112
Carboplatin + Paclitaxel - Drug Profile 114
WT1-Specific T Cells + Filgrastim + Cyclophosphamide + Fludarabine - Drug Profile 116
Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile 118
Docetaxel + Trabectedin + Pegfilgrastim - Drug Profile 119
BAY 43-9006 + Gemcitabine - Drug Profile 121
paclitaxel poliglumex - Drug Profile 122
topotecan hydrochloride - Drug Profile 123
NY-ESO-1b Peptide Vaccine + Montanide ISA-51 - Drug Profile 125
Avastin + Gemcitabine + Carboplatin - Drug Profile 126
docetaxel - Drug Profile 127
docetaxel - Drug Profile 128
Filgrastim + Carboplatin + Cyclophosphamide + Topotecan + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 129
Filgrastim + Carboplatin + Cyclophosphamide + Topotecan + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 131
MUC1-KLH Vaccine + QS21 - Drug Profile 133
abagovomab - Drug Profile 135
paclitaxel - Drug Profile 136
Taxol + Paraplatin - Drug Profile 137
cediranib maleate - Drug Profile 139
denileukin diftitox - Drug Profile 141
Paclitaxel + Carboplatin + Vorinostat - Drug Profile 143
Carboplatin + Paclitaxel - Drug Profile 145
temsirolimus - Drug Profile 146
Sargramostim + Ovarian Cancer Peptide Vaccine + Tetanus Toxoid Helper Peptide - Drug Profile 148
AMG 386 + Paclitaxel - Drug Profile 149
MLN8237 + Paclitaxel - Drug Profile 151
Taxotere + Eloxatin + Avastin - Drug Profile 152
TRC-105 - Drug Profile 154
Monoclonal antibody hu3S193 - Anti-LeY - Drug Profile 156
Pemetrexed + Carboplatin - Drug Profile 157
paclitaxel - Drug Profile 158
RAD001 + Avastin - Drug Profile 159
AMG-479 - Drug Profile 160
AMG-479 - Drug Profile 161
Avastin + Carboplatin + Paclitaxel - Drug Profile 162
Bevacizumab + Pemetrexed - Drug Profile 164
Bevacizumab + OSI-774 - Drug Profile 165
irofulven - Drug Profile 167
paclitaxel - Drug Profile 168
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 170
Paclitaxel + Cisplatin + Bevacizumab - Drug Profile 172
Bevacizumab + Abraxane - Drug Profile 173
lapatinib ditosylate - Drug Profile 174
Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 175
EGEN-001 - Drug Profile 177
Bevacizumab + Topotecan - Drug Profile 179
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 180
Carboplatin + Taxotere + Gemcitabine - Drug Profile 182
Cediranib Maleate + Olaparib - Drug Profile 184
Abraxane + Carboplatin - Drug Profile 185
Taxol + Carboplatin + Avastin - Drug Profile 186
paclitaxel - Drug Profile 187
Paclitaxel + Cisplatin - Drug Profile 188
RO-4929097 - Drug Profile 189
Etoposide + Irinotecan - Drug Profile 190
OCDC Dendritic Cell Vaccine - Drug Profile 191
Paclitaxel + Carboplatin - Drug Profile 192
doxorubicin - Drug Profile 193
Pegylated Liposomal Doxorubicin + Docetaxel - Drug Profile 194
Myocet + Gemzar - Drug Profile 196
doxorubicin - Drug Profile 197
Taxol + Paraplatin + Bevacizumab - Drug Profile 199
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 201
Irinotecan + Bevacizumab - Drug Profile 203
Paclitaxel + AZD0530 - Drug Profile 204
Carboplatin + Pralatrexate - Drug Profile 205
ABT-888 + Liposomal Doxorubicin Hydrochloride - Drug Profile 207
ABT-888 + Liposomal Doxorubicin Hydrochloride - Drug Profile 209
Fludarabine + Cyclophosphamide + Cyclosporine + Natural Killer Cells + IL-2 - Drug Profile 211
Topotecan + Cyclophosphamide + Paclitaxel + Melphalan + Cisplatin + Peripheral blood stem cell transplantation - Drug Profile 213
Oxaliplatin + Topotecan - Drug Profile 215
Paclitaxel +Carboplatin - Drug Profile 216
OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile 217
Alimta + Paraplatin - Drug Profile 219
Carboplatin + Glutathione + Paclitaxel - Drug Profile 220
Bortezomib + Carboplatin - Drug Profile 222
Paclitaxel + Reolysin - Drug Profile 223
Dendritic Cell Tumor Fusion Vaccine + Granulocyte Macrophage Colony Stimulating Factor - Drug Profile 224
Filgrastim + Carboplatin + Etoposide + Paclitaxel + Thiotepa + Topotecan + Stem Cell Transplantation - Drug Profile 226
GM-CSF + Dendritic Cell Tumor Fusion Vaccine + Imiquimod - Drug Profile 229
ABT-888 + Topotecan Hydrochloride - Drug Profile 231
Aldesleukin + Lymphokine-activated Killer Cells + Rituximab + Cyclophosphamide + Fludarabine Phosphate - Drug Profile 233
Carcinoembryonic antigen-expressing measles virus - Drug Profile 235
anastrazole - Drug Profile 236
Celecoxib + Cyclophosphamide - Drug Profile 237
Cisplatin + Paclitaxel + Alimta - Drug Profile 238
eribulin mesylate - Drug Profile 239
Filgrastim + Carboplatin + Cyclophosphamide + Paclitaxel + Topotecan Hydrochloride + Peripheral Blood Stem Cells Transplantation - Drug Profile 240
Filgrastim + Carboplatin + Cyclophosphamide + Paclitaxel + Topotecan Hydrochloride + Peripheral Blood Stem Cells Transplantation - Drug Profile 242
doxorubicin - Drug Profile 244
Cisplatin + Adriamycin + Cyclophosphamide - Drug Profile 245
paclitaxel albumin-stabilized nanoparticle formulation - Drug Profile 247
Gemcitabine + Cisplatin - Drug Profile 248
ABT-888 + Radiation Therapy - Drug Profile 249
AMG 386 + Carboplatin + Paclitaxel - Drug Profile 250
catumaxomab - Drug Profile 252
CA4P + Bevacizumab - Drug Profile 253
BIBF 1120 + Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 254
OC-L/Montanide ISA 51 VG + Ampligen + Prevnar - Drug Profile 256
ABT-767 - Drug Profile 257
Pegylated Liposomal Doxorubicin + Carboplatin - Drug Profile 258
Gemcitabine + Carboplatin - Drug Profile 259
pegaspargase - Drug Profile 260
²¹²Pb-TCMC-Trastuzumab - Drug Profile 261
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate - Drug Profile 262
OC-DC Vaccine + Bevacizumab + Cyclophosphamide + Fludarabine + CD3/CD28-Costimulated Vaccine-Primed Peripheral Blood Autologous T Cells - Drug Profile 263
Phenoxodiol + Cisplatin - Drug Profile 264
Phenoxodiol + Paclitaxel - Drug Profile 265
Peritoneal Tumor Therapeutics – Drug Profile Updates 266
Peritoneal Tumor Therapeutics – Discontinued Products 275
Peritoneal Tumor Therapeutics - Dormant Products 276
Peritoneal Tumor – Product Development Milestones 284
Featured News & Press Releases 284
Appendix 287
Methodology 287
Coverage 287
Secondary Research 287
Primary Research 287
Expert Panel Validation 287
Contact Us 288
Disclaimer 288

List of Tables
Number of Products Under Development for Peritoneal Tumor, H2 2012 21
Products under Development for Peritoneal Tumor – Comparative Analysis, H2 2012 22
Number of Products under Development by Companies, H2 2012 24
Number of Products under Development by Companies, H2 2012 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Comparative Analysis by Late Stage Development, H2 2012 31
Comparative Analysis by Mid Clinical Stage Development, H2 2012 32
Comparative Analysis by Early Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 42
Boehringer Ingelheim GmbH, H2 2012 43
F. Hoffmann-La Roche Ltd., H2 2012 44
Abbott Laboratories, H2 2012 45
Amgen Inc., H2 2012 46
Sanofi-Aventis, H2 2012 47
Eli Lilly and Company, H2 2012 48
Millennium Pharmaceuticals, Inc., H2 2012 49
Cell Therapeutics, Inc., H2 2012 50
Bayer AG, H2 2012 51
Marshall Edwards, Inc., H2 2012 52
MabVax Therapeutics, Inc., H2 2012 53
CritiTech, Inc., H2 2012 54
TRACON Pharmaceuticals, Inc., H2 2012 55
RECEPTA Biopharma S.A., H2 2012 56
Theradex Systems, Inc., H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Peritoneal Tumor Therapeutics – Drug Profile Updates 276
Peritoneal Tumor Therapeutics – Discontinued Products 285
Peritoneal Tumor Therapeutics – Dormant Products 286
Peritoneal Tumor Therapeutics – Dormant Products (Contd..1) 287
Peritoneal Tumor Therapeutics – Dormant Products (Contd..2) 288
Peritoneal Tumor Therapeutics – Dormant Products (Contd..3) 289
Peritoneal Tumor Therapeutics – Dormant Products (Contd..4) 290
Peritoneal Tumor Therapeutics – Dormant Products (Contd..5) 291
Peritoneal Tumor Therapeutics – Dormant Products (Contd..6) 292
Peritoneal Tumor Therapeutics – Dormant Products (Contd..7) 293

List of Figures
Number of Products under Development for Peritoneal Tumor, H2 2012 21
Products under Development for Peritoneal Tumor – Comparative Analysis, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 31
Mid Clinical Stage Products, H2 2012 32
Early Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Route of Administration, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos